An investigator-initiated clinical study in patients with refractory or recurrent solid tumors: 'R-ISV-FOLactis' trial.
Future Oncol
; : 1-8, 2024 Jul 21.
Article
in En
| MEDLINE
| ID: mdl-39034683
ABSTRACT
Aim:
In situ vaccination, a kind of therapeutic cancer vaccine, can be realized by radiotherapy and intratumoral immune injection. This study combines intratumoral injection, radiotherapy and PD-1 blockade for synergistic antitumor effect. Materials &methods:
Patients with advanced solid tumors who are unresponsive or intolerant to standard treatment will be treated with hypofractionated radiotherapy, intratumoral injection of FOLactis, PD-1 blockade. The primary end point is to observe the efficacy and safety, with the secondary end point to evaluate abscopal effects and the correlation between the immunological rationale and efficacy.Discussion:
The combined regimen will be utilized to trigger antitumor immunity and is expected to be feasible and effective and provide a novel option for the comprehensive treatment of cancer.Clinical Trial Registration ChiCTR2200060660 (ChiCTR.gov.cn).
[Box see text].
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Future Oncol
Year:
2024
Document type:
Article
Affiliation country:
China